Fusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order

April 25, 2024

https://www.prnewswire.com/news-releases/fusion-pharmaceuticals-mails-circular-for-special-meeting-of-shareholders-and-announces-receipt-of-interim-order-302128066.html

HAMILTON, ON and BOSTON, April 25, 2024 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjucates (RCs) as precision medicines, today announced that it has filed and is in the process of mailing the management information circular and proxy statement (the “Circular“) and related materials for the special meeting (the “Meeting“) of Fusion’s shareholders (the “Shareholders“) to approve the previously announced arrangement with AstraZeneca plc (“AstraZeneca“) under the Canada Business Corporations Act (the “Arrangement“).

Read more at prnewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.